Volume growth masks margin collapse and execution risk

Delivered 3,946.2 Cr; domestic volume +25% YoY but revenue only +2% (industry grew 15%)

RM cost inflation confirmed 20%; price increases only 5% taken Q1, 8-9% planned Q2+ totaling ~11–13% vs ~20% RM inflation lag

EBITDA margin 6.8% vs 10.9% prior year (310 bps compression); cash profit down 45% YoY; PAT down 73% YoY to ₹43 Cr

Mexico revenue down 82% YoY; no quantified recovery path or timeline; promised similar topline to Q3/Q4 but undefined 'normalcy' baseline

Volume figures confirmed in Q&A; but India standalone revenue growth only 14%, indicating significant price/mix headwind

FY26 historical margins ~11-13%; FY27 full-year guidance now 10-11% (H2 recovery to 11-13% contingent on RM stabilization). Q1 weakness dragged full-year down.

Prior calls did not highlight Mexico as a risk. Q1FY27 saw 82% YoY revenue decline due to geopolitical supply issues and labor negotiations. Consolidated margin hurt by Mexico's poor performance.

Prior guidance: price increases (4-7% + 5-6%) would offset RM inflation (18-20%). Actual: 5% taken Q1, RM +20%; lag persists into Q2 (+8-10% expected RM vs +8-9% price). Not a miss on plan, but execution confirms margin pressure through Q2.

Farm segment volume +31% YoY, supporting earlier narrative of rural market growth. No change to strategic priority; execution confirmed.

NSR increase ~4% YoY, ~5% sequential. OEM prices increased but lag in Q1; reflect in Q2+. Mix-down from lower-margin products also contributed.

Geopolitical disruptions (shipping, bead wire availability from China), labor slowdown, all now resolved. Back to normal production, better results expected in remaining 3 quarters.

Q1 price increase ~5% monthly staggered basis; Q2+ expecting 8-9% range; cumulative 11% already taken in replacement market.

Double-digit revenue growth (10-11% similar to FY26); margins 10-11% full-year, rising to 11-13% in H2 as RM prices stabilize and price hikes flow through.

Yes, price hikes plus cost reduction measures, higher leverage, product mix, premiumization should offset RM inflation minus 1-2%; margin recovery from Q2 onwards progressive.

India 95%, consolidated 80%. ₹4,980 Cr expansion adds 24% over 4 years; 7% by FY28 (TBR + PCR balancing at Banmore plant).

Yes, EV tyre wear 5-10% faster due to high torque. Shorter life accelerates replacement demand, offsetting cycle reduction.

Standalone domestic volume +25% YoY, mid-single digit sequential. Mix: TBR 56%, PCR 27%, 2/3W 5%, others 12%. PCR mix improving, high-rim tyres 35% of PCR.

Monthly staggered basis throughout Q1, balanced with volume offtake to avoid customer impact. Not front-loaded or back-loaded.

Already seeing softening in rubber prices. Hopeful prices will fall further by next quarter.

Correction: slowdown, not strike. Same production levels already started, back to normal. May take few more days. Hoping for similar topline to Q3/Q4.

USMCA renewed for 10 years. Mexico-USA duty structure expected to be favorable towards Mexico.

Based on volume momentum (+25% Q1), price increases (5% Q1, 8-9% Q2+), and capex ramp (7% capacity addition by FY28). Contingent on sustained demand and Mexico recovery.

Q1 at 6.8% due to RM lag. FY27 assumes RM stabilization by H2, price hikes flow through (cumulative 8-9% more after Q1), cost reduction measures, higher operating leverage.

Language signals uncertainty on FY27 margin recovery; multiple conditions must align (RM stabilization, price acceptance, volume growth).

Already approved; 7% capacity addition by FY28, 24% by 2029. Phased disbursement; debt increase ₹500-700 Cr expected FY27.

20% RM inflation in Q1; CFO expects 8-10% further in Q2 from higher-cost inventory. Price increases only 5% Q1, 8-9% planned Q2 = lag of 3-7%. H2 stabilization contingent on commodity markets, not management control.

Mexico revenue down 82% YoY in Q1. Blamed on shipping delays (West Asia crisis), bead wire availability from China (geopolitical), and labor slowdown (productivity negotiations). Consolidated margin 6.8% vs India standalone likely 8-9%+ suggests Mexico at or below 2-3% margin. Mexico recovery timeline vague; management promised 'similar topline to Q3/Q4' without defining baseline.

Management pricing 5% in Q1 'monthly staggered' to avoid customer impact. Q2+ planning 8-9% more, totaling ~13-14% cumulative. If customers balk at cumulative ~13%, margin gains erode and volume growth slows. CFO noted caution 'we are basically inching up the prices so that such increase does not pinch the customer'. Q1 revenue only +2% despite +25% volume signals mix-down; Q2+ price elasticity unknown.

Debt-to-EBITDA at 2.56x (up from 2.13x Q4FY26). Debt-to-equity at 0.81x (up from 0.73x). If capex overruns or FY27 margins miss 10-11% guidance, leverage rises sharply. Large capex on 7% utilization headroom (3% of 95% India capacity already unutilized) means risk of overlevering before new capacity ramps. FY27 capex disbursements also eating cash, pressed working capital due to higher RM prices.

₹4,980 Cr capex assumes strong demand absorption. PCR is highest-margin segment (16-inch+ tyres now 35% of mix, premium). But market share concentrated (industry typically 3-4 large players). If competitor also adds capacity or demand growth slows, utilization of new PCR/TBR lines at risk. No specific market share target or demand CAGR stated for the new capacity.